Tafamidis News
Tafamidis currently has 0 news articles, with 20 predicted indications.
This page combines the AI-predicted indications for Tafamidis with the latest health news. Indications highlighted in orange have recent news coverage.
Drug Information
- Original indication: Vyndaqel is indicated for the treatment of transthyretin amyloidosis in adult patients with stage-1 symptomatic polyneuropathy to delay peripheral neurologic impairment.
- Evidence level: L5
- Predicted indications (20):
- primary release disorder of platelets (89.3%)
- thrombocytopenic purpura (88.7%)
- pseudo-von Willebrand disease (87.9%)
- Glanzmann thrombasthenia (85.8%)
- primary amyloidosis (85.0%)
- acquired amyloid peripheral neuropathy (84.8%)
- primary hyperoxaluria (84.3%)
- dermis disease (83.4%)
- biotin metabolic disease (83.3%)
- mixed-type autoimmune hemolytic anemia (82.3%)
- drug-induced autoimmune hemolytic anemia (82.0%)
- proteinuria (81.8%)
- inherited thrombophilia (81.0%)
- amyloidosis cutis dyschromia (80.8%)
- nodular cutaneous amyloidosis (80.8%)
- macular amyloidosis (80.8%)
- neonatal autoimmune hemolytic anemia (80.7%)
- Ledderhose disease (80.4%)
- familial apolipoprotein C-II deficiency (78.5%)
- infantile digital fibromatosis (78.2%)
Related News (0)
No related news yet. When news mentions this drug, it will be collected and shown here automatically.
Disclaimer: The news on this page is collected automatically and is for research reference only; it does not constitute medical advice.